(Press-News.org) A new-generation lung cancer drug has shown an impressive ability to prevent disease progression when administered as a first-line treatment in patients with advanced disease, investigators reported at the 35th Congress of the European Society for Medical Oncology (ESMO).
Preliminary results from an ongoing Phase-II trial of the drug PF299804 (PF-299) showed that close to 85% of patients whose cancers harbor mutated forms of the EGFR gene have remained progression-free for at least nine months, reported Dr Tony Mok from the Chinese University of Hong Kong.
While some existing drugs reversibly inhibit the cancer-linked receptor HER-1 (also known as EGFR), PF-299 is a 'pan-HER' inhibitor, which irreversibly inhibits several members of the HER family, including EGFR, HER-2 and HER-4.
"We know that PF-299 is a different compound than drugs such as erlotinib and gefitinib, targeting multiple receptors on the HER pathway," Dr Mok said. "We also know from preclinical work that PF-299 inhibits signaling in both wild-type and mutant EGFR, including forms of NSCLC that are resistant to EGFR inhibitors such as erlotinib and gefitinib."
The current trial includes patients with advanced non-small cell lung cancer and no prior systemic treatment for their disease. All were either non-smokers or light smokers, or were known to have EGFR mutations.
So far, 74 of 80 planned patients have enrolled. Of the 41 with known EGFR status, 27 had activating mutations.
Each patient was administered either 30mg or 45mg of PF-299 once daily, and were assessed every 28 days. After 9 months of treatment, 57.1% of patients overall, and 84.7% of those patients with EGFR mutations, remained progression-free, Dr Mok reported. The expected median progression-free survival with standard-of-care chemotherapy in this patient population is approximately six months.
"Even though these data are preliminary and patients are still being followed, the percentage of patients with EGFR mutations who are progression-free at six months is particularly promising, with 85% of patients remaining progression-free by nine months," Dr Mok said.
"We are excited by these encouraging early results, as they support our hypothesis that these next generation agents targeting multiple receptors on the HER pathway may offer an advantage," he said.
Dr Mok noted that in another study recently presented, PF299 was reported to be better than erlotinib in a randomized head-to-head Phase-II study in patients with advanced NSCLC who had progressed on at least one prior chemotherapy regimen.
"Our new results, even though preliminary, also suggest that PF-299 could offer an improvement over currently available options as a first-line treatment in both Asian and non-Asian patients with advanced NSCLC selected for likelihood of an EGFR activating mutation."
""The results of this trial are encouraging, particularly because 85% of EGFR-mutated patients treated with PF-299 as first-line remained progression-free at 9 months," commented Dr Enriqueta Felip, from Vall d'Hebron Hospital in Barcelona, Spain.
INFORMATION: END
An ongoing Phase-II trial investigating a new, targeted therapy for metastatic urothelial cancer has generated promising early results, Italian researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.
Urothelial cancers affect the tissue lining the inner surfaces of the bladder and other parts of the urinary system. In cases of metastatic disease, median survival is approximately 12-15 months and there is a 10-15% chance of prolonging it by the use of standard chemotherapy regimens, particularly in otherwise healthy ...
The results of a large Phase-III clinical trial have shown that the drug everolimus delays tumor progression in patients with a hard-to-treat group of rare cancers that affect particular hormone-producing cells.
At the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Marianne Pavel from Charité University in Berlin, Germany reported that everolimus improved progression-free survival by 5.1 months in patients with advanced neuroendocrine tumors.
Neuroendocrine tumors are slow-growing malignancies that originate from cells of the body's neuroendocrine ...
A new class of compounds identified by researchers at Emory University School of Medicine could be developed into drugs for the treatment of schizophrenia. The compounds enhance signaling by molecules in the brain called NMDA receptors, which scientists believe are functioning at low levels in people with schizophrenia.
Led by Stephen Traynelis, PhD, professor of pharmacology, a team of Emory researchers sifted through thousands of chemicals and found one, called CIQ, which could selectively enhance the function of certain NMDA receptors without affecting others.
The ...
Iowa City, IA—October 11, 2010— A new study published in Applied Cognitive Psychology finds that college-aged men are very likely to remember a woman's initial sexual interest (attraction or rejection), especially when the woman in question is thought to be attractive, is dressed more provocatively, and expresses positive sexual interest.
In the study the men were shown full-body photographs of college-aged women who expressed cues of sexual interest or rejection. The participating males represented mixed sexual histories, and a capacity for varying degrees of sexually ...
GAINESVILLE, Fla. --- University of Florida researchers presenting new fossil evidence of an exceptionally well-preserved 55-million-year-old North American mammal have found it shares a common ancestor with rodents and primates, including humans.The study published today in the online edition of the Zoological Journal of the Linnean Society, describes the cranial anatomy of the extinct mammal, Labidolemur kayi.
High resolution CT scans of the specimens allowed researchers to study minute details in the skull, including bone structures smaller than one-tenth of a millimeter. ...
The genetic inherited material DNA was long viewed as the sole bearer of hereditary information. The function of its packaging proteins, the histones, was believed to be exclusively structural. Additional genetic information can be stored, however, and passed on to subsequent generations through chemical changes in the DNA or histones. Scientists from the Max Planck Institute for Biophysical Chemistry in Göttingen have succeeded in creating an experimental system for testing the function of such chemical histone modifications and their influence on the organism. Chemical ...
More brilliant X-rays, more cost-effective methods for developing new energy sources and advanced manufacturing processes are just some of the benefits which may come from a novel technology, proven at the theoretical level by a consortium of British and European laser scientists. The research, led by scientists at the Science and Technology Facilities Council's Central Laser Facility is published in this week's edition of Nature Physics (October 10 2010).
A team of scientists from the Instituto Superior Tecnico in Lisbon, Imperial College London, and the Universities ...
A University of Colorado at Boulder space dust counter designed, tested and operated by students that is flying aboard NASA's New Horizons mission to Pluto now holds the record for the most distant working dust detector ever to travel through space.
The instrument on the New Horizons mission -- officially named the Venetia Burney Student Dust Counter, or SDC, after an 11-year-old English girl who named Pluto more than 75 years ago -- reached a distance of 1.67 billion miles from Earth on Oct. 10. Designed by a student team from CU-Boulder's Laboratory for Atmospheric ...
Providence, RI---It was a mathematician, Joseph Fourier (1768-1830),
who coined the term "greenhouse effect". That this term, so commonly
used today to describe human effects on the global climate, originated
with a mathematician points to the insights that mathematics can offer
into environmental problems. Three articles in the November 2010
issue of the Notices of the American Mathematical Society examine ways
in which mathematics can contribute to understanding environmental and
ecological issues.
"Earthquakes and Weatherquakes: Mathematics and Climate Change", ...
Prenatal treatment of congenital toxoplasmosis with antibiotics might substantially reduce the proportion of infected fetuses that develop serious neurological sequelae (brain damage, epilepsy, deafness, blindness, or developmental problems) or die, and could be particularly effective in fetuses whose mothers acquired Toxoplasma gondii, the parasite that causes toxoplasmosis, during the first third of pregnancy. These are the findings of an observational study by Ruth Gilbert from the UCL Institute of Child Health, London, UK, and colleagues and published in this week's ...
